— Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported earnings of $2.71 per share in the fourth-quarter 2019, vs. $2.60 per share expected.
— Total revenue rose 23% to $1.38 billion, vs. $1.31 billion expected. SOLIRIS net sales rose 11% to $3.94 billion.
— For FY20, Alexion expects revenues of $5.50 – $5.56 billion. Adjusted EPS is projected to be $10.65 to $10.85.
— ALXN stock gained 1.8% during pre-market hours immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Earnings Preview: What to look for when Netflix (NFLX) reports Q4 2025 results
Netflix, Inc. (NASDAQ: NFLX) is expected to report Q4 results on January 20, amid expectations for strong revenue and earnings growth. The company is navigating a shifting streaming landscape where
What to look for when United Airlines (UAL) reports its Q4 2025 earnings results
Shares of United Airlines (NASDAQ: UAL) stayed red on Thursday. The stock has gained 15% over the past three months. The airline is scheduled to report its earnings results for
Infographic: How Constellation Brands (STZ) performed in Q3 2026
Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to
